MAGED2 participates in cell cycle regulation and participates in the process of methionine deprivation which leads to a targetable vulnerability in triple-negative breast cancer cells by promoting Trail receptor-2 expression (Strekalova et al., 2015). The gene discussed is MAGED2; the disease is triple-negative breast carcinoma.